# CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

> **NCT03579927** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- CD19 Positive
- Mantle Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma

## Interventions

- **PROCEDURE:** Autologous Hematopoietic Stem Cell Transplantation
- **DRUG:** Carmustine
- **DRUG:** Cytarabine
- **DRUG:** Etoposide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Melphalan
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Umbilical Cord Blood-derived Natural Killer Cells

## Key facts

- **NCT ID:** NCT03579927
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-10-03
- **Primary completion:** 2019-10-03
- **Final completion:** 2019-10-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of Funding
- **Last updated:** 2020-01-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03579927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03579927, "CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03579927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*